Investors

Latest News

Expedeon introduces InnovaCoat® GOLD-Carboxyl nanoparticles

July 25th, 2016

Functionalized gold nanoparticles for easy, fast covalent conjugation of antibodies Cambridge, UK, 25 July 2016: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced the launch of a carboxylated derivative of its unique InnovaCoat® GOLD 40 nm nanoparticles. The new product enables customers to quickly generate highly stable covalent gold-antibody conjugates at…

View

Expedeon Expands UK Facility & Increases Laboratory Space

April 25th, 2016

Expedeon Expands UK Facility & Increases Laboratory Space Cambridge, UK, 25 April 2016: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced it has expanded its UK footprint to enable the company to increase its laboratory space. Innova’s sales and marketing teams have moved from the Babraham Research Park to Ashwell Point…

View

Expedeon Introduces New LATEX One-Step Conjugation Kits

February 15th, 2016

New red, blue and black kits for conjugation of antibodies and proteins to latex beads Cambridge, UK, 15 February 2016: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced the launch of new red, black and blue 400nm LATEX conjugation kits. Expedeon’ LATEX conjugation kits are one-step kits for the covalent conjugation…

View

Expedeon Appoints Steve Howell as Non-Executive Director

February 1st, 2016

Cambridge, UK, 01 February 2016: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced the appointment of Professor Steve Howell to the Board of Directors. Steve has over 20 years of experience building and growing life science enterprises, including founding life science investment company Innova Partnerships in 2006. Prior to this he…

View

Expedeon Introduces Thunder-Link® PLUS

January 18th, 2016

New improved antibody oligonucleotide conjugation kit Cambridge, UK, 18 January 2016: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced the launch of Thunder-Link® PLUS, a new and improved version of the original Thunder-Link kit, enabling even faster and more efficient oligonucleotide conjugation. The new kit offers all of the advantages of…

View

Expedeon Installs Colloidal Gold Bulk Production Capability

November 16th, 2015

Bulk production facility enables company to support large diagnostics customers Cambridge, UK, 16 November 2015: Expedeon (Innova), a specialist provider of bioconjugation products and services, today announced the installation of bulk production capability for its colloidal gold nanoparticle products. The move enables the company to support any scale of operation, including the largest players in…

View

Expedeon and Mologic Sign Supply and Licensing Agreement

July 27th, 2015

License covers use of Innova’s Lightning-Link and InnovaCoat GOLD technologies in Mologic’s kits and services Cambridge and Bedford, UK, 27 July 2015: Expedeon (Innova), a specialist provider of bioconjugation products and services, and Mologic, a specialist diagnostic development company and molecular reagent innovator, announced today the signing of a supply and licensing agreement for use…

View

Expedeon Introduces Lightning-Link Rapid Bioconjugation Kits

November 3rd, 2014

New kits enable customers to conjugate primary antibodies in 20 minutes Cambridge, UK, 3rd November 2014: Expedeon (Innova), a specialist provider of bioconjugation products and services, announced today the launch of new antibody and protein labelling kits within its Lightning-Link® Rapid range. These kits enable researchers to label primary antibodies or other proteins in just…

View

Expedeon Introduces InnovaGOLD Nanoparticles

August 28th, 2014

New ultra-high quality gold nanoparticles simplify assay development and improve the sensitivity of immunoassays Cambridge, UK, 28th August 2014: Expedeon (Innova), a specialist provider of bioconjugation products and services, announced today the commercial launch of InnovaGOLD, a new range of ultra-high quality gold nanoparticles that have demonstrated improved sensitivity, stability and reproducibility in immunoassays compared…

View

Expedeon and TGR BioSciences Announce Co-Marketing Agreement for Core Technologies

January 16th, 2014

Combining Innova’s Lightning-Link® conjugation kits with TGR’s CaptSure™ ELISA technology simplifies ELISA development and improves sensitivity Cambridge, UK and Adelaide, Australia, 16 January 2014: TGR BioSciences Pty Ltd (TGR), a life sciences company focused on the development of rapid, high sensitivity ELISA systems using their CaptSure technology, and Expedeon (Innova), a specialist provider of bioconjugation…

View

Expedeon Ltd achieves InnovaCoat® key scale-up target

November 12th, 2013

Expedeon, the inventor of high quality, easy to use bioconjugation kits, is pleased to announce it has reached yet another significant milestone of its programme funded by the UK’s innovation agency, the Technology Strategy Board, by meeting a key scale-up target for the production of its unique InnovaCoat® gold nanoparticle conjugation reagents. Traditional passive methods…

View

Expedeon Develops Site-Specific Bioconjugation Technology

August 27th, 2013

Expedeon, the inventor of the world’s easiest to use antibody labeling kits, is pleased to announce the launch of a site-specific bioconjugation technology for attaching antibodies to gold nanoparticles. Innova’s core business is ‘bioconjugation’ – the joining of two molecules to form a hybrid ‘conjugate’. Conjugates are used in diagnostic tests in hospitals and research…

View